Which has preferable earnings and valuation, AXSM or HCM?

HUTCHMED has lower revenue, but higher earnings than Axsome Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Axsome Therapeutics $638.50M 13.81 -$183.17M -$3.75 N/A HUTCHMED $548.51M 4.48 $456.91M N/A N/A

Does the media prefer AXSM or HCM?

In the previous week, Axsome Therapeutics had 6 more articles in the media than HUTCHMED. MarketBeat recorded 9 mentions for Axsome Therapeutics and 3 mentions for HUTCHMED. Axsome Therapeutics' average media sentiment score of 0.13 beat HUTCHMED's score of -0.20 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral HUTCHMED 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, HCM or CRNX?

HUTCHMED has higher revenue and earnings than Crinetics Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 4.48 $456.91M N/A N/A Crinetics Pharmaceuticals $7.70M 1,170.54 -$465.32M -$5.04 N/A

Which has stronger earnings and valuation, LNTH or HCM?

HUTCHMED has lower revenue, but higher earnings than Lantheus. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.24 $233.56M $4.14 24.19 HUTCHMED $548.51M 4.48 $456.91M N/A N/A

Is LNTH or HCM more profitable?

Lantheus has a net margin of 17.69% compared to HUTCHMED's net margin of 0.00%. Lantheus' return on equity of 28.10% beat HUTCHMED's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 17.69% 28.10% 14.35% HUTCHMED N/A N/A N/A

Does the media prefer LNTH or HCM?

In the previous week, Lantheus and Lantheus both had 3 articles in the media. Lantheus' average media sentiment score of 0.00 beat HUTCHMED's score of -0.20 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HUTCHMED 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, HCM or AMRX?

HUTCHMED has higher earnings, but lower revenue than Amneal Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 4.48 $456.91M N/A N/A Amneal Pharmaceuticals $3.02B 2.11 $72.06M $0.49 40.63

Does the media favor HCM or AMRX?

In the previous week, Amneal Pharmaceuticals had 4 more articles in the media than HUTCHMED. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 3 mentions for HUTCHMED. Amneal Pharmaceuticals' average media sentiment score of 0.38 beat HUTCHMED's score of -0.20 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, HCM or BLTE?

HUTCHMED has higher revenue and earnings than Belite Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 4.48 $456.91M N/A N/A Belite Bio N/A N/A -$77.61M -$2.73 N/A

Is HCM or BLTE more profitable?

HUTCHMED's return on equity of 0.00% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets HUTCHMED N/A N/A N/A Belite Bio N/A -11.84% -11.62%

Does the media prefer HCM or BLTE?

In the previous week, Belite Bio had 2 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for Belite Bio and 3 mentions for HUTCHMED. Belite Bio's average media sentiment score of 0.39 beat HUTCHMED's score of -0.20 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Belite Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

HUTCHMED (HCM) Competitors

$14.10 +0.43 (+3.15%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$14.06 -0.04 (-0.28%)

As of 10/9/2026 04:10 PM Eastern

Compare

HCM vs. AXSM, CRNX, LNTH, AMRX, and BLTE

Should you buy HUTCHMED stock or one of its competitors? HUTCHMED's main competitors and comparable companies include Axsome Therapeutics (AXSM), Crinetics Pharmaceuticals (CRNX), Lantheus (LNTH), Amneal Pharmaceuticals (AMRX), and Belite Bio (BLTE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does HUTCHMED compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and HUTCHMED (NASDAQ:HCM) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Axsome Therapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market.

HUTCHMED has lower revenue, but higher earnings than Axsome Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	13.81	-$183.17M	-$3.75	N/A
HUTCHMED	$548.51M	4.48	$456.91M	N/A	N/A

HUTCHMED has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -24.68%. HUTCHMED's return on equity of 0.00% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
HUTCHMED	N/A	N/A	N/A

Axsome Therapeutics currently has a consensus target price of $275.74, indicating a potential upside of 63.79%. HUTCHMED has a consensus target price of $14.87, indicating a potential upside of 5.44%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Axsome Therapeutics is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86
HUTCHMED	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Axsome Therapeutics had 6 more articles in the media than HUTCHMED. MarketBeat recorded 9 mentions for Axsome Therapeutics and 3 mentions for HUTCHMED. Axsome Therapeutics' average media sentiment score of 0.13 beat HUTCHMED's score of -0.20 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
HUTCHMED	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 3.6% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Axsome Therapeutics beats HUTCHMED on 10 of the 14 factors compared between the two stocks.

How does HUTCHMED compare to Crinetics Pharmaceuticals?

HUTCHMED (NASDAQ:HCM) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 3.6% of HUTCHMED shares are held by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, HUTCHMED had 3 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 3 mentions for HUTCHMED and 0 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 0.00 beat HUTCHMED's score of -0.20 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
HUTCHMED	Neutral
Crinetics Pharmaceuticals	Neutral

HUTCHMED presently has a consensus target price of $14.87, indicating a potential upside of 5.44%. Crinetics Pharmaceuticals has a consensus target price of $83.44, indicating a potential downside of 1.77%. Given HUTCHMED's stronger consensus rating and higher probable upside, equities research analysts plainly believe HUTCHMED is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

HUTCHMED has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market.

HUTCHMED has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. HUTCHMED's return on equity of 0.00% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

HUTCHMED has higher revenue and earnings than Crinetics Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	4.48	$456.91M	N/A	N/A
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A

Summary

HUTCHMED beats Crinetics Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does HUTCHMED compare to Lantheus?

Lantheus (NASDAQ:LNTH) and HUTCHMED (NASDAQ:HCM) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

In the previous week, Lantheus and Lantheus both had 3 articles in the media. Lantheus' average media sentiment score of 0.00 beat HUTCHMED's score of -0.20 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HUTCHMED	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus currently has a consensus price target of $108.11, suggesting a potential upside of 7.95%. HUTCHMED has a consensus price target of $14.87, suggesting a potential upside of 5.44%. Given Lantheus' higher possible upside, analysts clearly believe Lantheus is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
HUTCHMED	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Lantheus has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market.

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 3.6% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Lantheus has a net margin of 17.69% compared to HUTCHMED's net margin of 0.00%. Lantheus' return on equity of 28.10% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
HUTCHMED	N/A	N/A	N/A

HUTCHMED has lower revenue, but higher earnings than Lantheus.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.24	$233.56M	$4.14	24.19
HUTCHMED	$548.51M	4.48	$456.91M	N/A	N/A

Summary

Lantheus beats HUTCHMED on 8 of the 14 factors compared between the two stocks.

How does HUTCHMED compare to Amneal Pharmaceuticals?

HUTCHMED (NASDAQ:HCM) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Amneal Pharmaceuticals had 4 more articles in the media than HUTCHMED. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 3 mentions for HUTCHMED. Amneal Pharmaceuticals' average media sentiment score of 0.38 beat HUTCHMED's score of -0.20 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HUTCHMED has higher earnings, but lower revenue than Amneal Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	4.48	$456.91M	N/A	N/A
Amneal Pharmaceuticals	$3.02B	2.11	$72.06M	$0.49	40.63

HUTCHMED has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 3.6% of HUTCHMED shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

HUTCHMED presently has a consensus price target of $14.87, indicating a potential upside of 5.44%. Amneal Pharmaceuticals has a consensus price target of $21.00, indicating a potential upside of 5.47%. Given Amneal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Amneal Pharmaceuticals is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Amneal Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Amneal Pharmaceuticals has a net margin of 5.05% compared to HUTCHMED's net margin of 0.00%. HUTCHMED's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Summary

Amneal Pharmaceuticals beats HUTCHMED on 11 of the 15 factors compared between the two stocks.

How does HUTCHMED compare to Belite Bio?

HUTCHMED (NASDAQ:HCM) and Belite Bio (NASDAQ:BLTE) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

HUTCHMED has higher revenue and earnings than Belite Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	4.48	$456.91M	N/A	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

In the previous week, Belite Bio had 2 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for Belite Bio and 3 mentions for HUTCHMED. Belite Bio's average media sentiment score of 0.39 beat HUTCHMED's score of -0.20 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

HUTCHMED currently has a consensus price target of $14.87, indicating a potential upside of 5.44%. Belite Bio has a consensus price target of $218.73, indicating a potential upside of 41.58%. Given Belite Bio's higher possible upside, analysts clearly believe Belite Bio is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

HUTCHMED has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, indicating that its stock price is 223% less volatile than the broader market.

HUTCHMED's return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Belite Bio	N/A	-11.84%	-11.62%

Summary

HUTCHMED beats Belite Bio on 8 of the 13 factors compared between the two stocks.

Get HUTCHMED News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HCM vs. The Competition

Export

Metric	HUTCHMED	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.38B	$12.35B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	N/A	797.58	274.15	26.16
Price / Sales	4.48	757.87	590.48	94.54
Price / Cash	5.07	85.97	76.38	53.09
Price / Book	1.97	10.71	11.21	6.34
Net Income	$456.91M	$2.84B	$3.50B	$381.90M
7 Day Performance	-0.70%	-0.93%	-0.90%	-1.41%
1 Month Performance	7.47%	-4.91%	-4.44%	-3.48%
1 Year Performance	-6.50%	-4.13%	6.96%	1.16%

HUTCHMED Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HCM HUTCHMED	1.0957 of 5 stars	$14.10 +3.1%	$14.87 +5.4%	-12.0%	$2.38B	$548.51M	N/A	1,796
AXSM Axsome Therapeutics	3.43 of 5 stars	$175.64 -0.8%	$275.84 +57.1%	+37.4%	$9.18B	$776.57M	N/A	925	Analyst Forecast
CRNX Crinetics Pharmaceuticals	0.9096 of 5 stars	$84.95 flat	$83.44 -1.8%	N/A	$9.01B	$7.70M	N/A	210
LNTH Lantheus	3.1642 of 5 stars	$100.02 -0.2%	$108.11 +8.1%	+91.2%	$6.53B	$1.54B	24.17	1,193
AMRX Amneal Pharmaceuticals	3.5497 of 5 stars	$20.44 +0.4%	$21.00 +2.7%	+93.5%	$6.52B	$3.12B	41.67	8,500	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HCM) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HUTCHMED (HCM) Competitors

HCM vs. AXSM, CRNX, LNTH, AMRX, and BLTE

How does HUTCHMED compare to Axsome Therapeutics?

Summary

How does HUTCHMED compare to Crinetics Pharmaceuticals?

Summary

How does HUTCHMED compare to Lantheus?

Summary

How does HUTCHMED compare to Amneal Pharmaceuticals?

Summary

How does HUTCHMED compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCM vs. The Competition

HUTCHMED Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HUTCHMED (HCM) Competitors

HCM vs. AXSM, CRNX, LNTH, AMRX, and BLTE

How does HUTCHMED compare to Axsome Therapeutics?

Which has more risk and volatility, AXSM or HCM?

Which has preferable earnings and valuation, AXSM or HCM?

Is AXSM or HCM more profitable?

Do analysts prefer AXSM or HCM?

Does the media prefer AXSM or HCM?

Do institutionals and insiders have more ownership in AXSM or HCM?

Summary

How does HUTCHMED compare to Crinetics Pharmaceuticals?

Do insiders & institutionals believe in HCM or CRNX?

Does the media favor HCM or CRNX?

Do analysts recommend HCM or CRNX?

Which has more volatility and risk, HCM or CRNX?

Is HCM or CRNX more profitable?

Which has preferable valuation and earnings, HCM or CRNX?

Summary

How does HUTCHMED compare to Lantheus?

Does the media prefer LNTH or HCM?

Do analysts rate LNTH or HCM?

Which has more risk and volatility, LNTH or HCM?

Do institutionals and insiders have more ownership in LNTH or HCM?

Is LNTH or HCM more profitable?

Which has stronger earnings and valuation, LNTH or HCM?

Summary

How does HUTCHMED compare to Amneal Pharmaceuticals?

Does the media favor HCM or AMRX?

Which has preferable valuation and earnings, HCM or AMRX?

Which has more risk & volatility, HCM or AMRX?

Do insiders and institutionals believe in HCM or AMRX?

Do analysts rate HCM or AMRX?

Is HCM or AMRX more profitable?

Summary

How does HUTCHMED compare to Belite Bio?

Which has stronger valuation and earnings, HCM or BLTE?

Does the media prefer HCM or BLTE?

Do institutionals & insiders believe in HCM or BLTE?

Do analysts rate HCM or BLTE?

Which has more risk & volatility, HCM or BLTE?

Is HCM or BLTE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCM vs. The Competition

HUTCHMED Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools